Stock Worth Mentioning Today: Is Opko Health Inc. a Buy? The Stock Rises Again

Stock Worth Mentioning Today: Is Opko Health Inc. a Buy? The Stock Rises Again

The stock of Opko Health Inc. (NASDAQ:OPK) is a huge mover today! About 2.09M shares traded hands. Opko Health Inc. (NASDAQ:OPK) has declined 5.45% since April 14, 2016 and is downtrending. It has underperformed by 10.14% the S&P500.
The move comes after 6 months positive chart setup for the $5.79 billion company. It was reported on Nov, 16 by Barchart.com. We have $16.32 PT which if reached, will make NASDAQ:OPK worth $3.18B more.

According to Zacks Investment Research, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.”

Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 0.16, from 0.84 in 2016Q1. The ratio is positive, as 33 funds sold all Opko Health Inc. shares owned while 63 reduced positions. 22 funds bought stakes while 74 increased positions. They now own 102.34 million shares or 2.14% more from 100.19 million shares in 2016Q1.
The New York-based M&R Mgmt Inc has invested 0.02% in Opko Health Inc. (NASDAQ:OPK). Stevens Capital Mngmt L P accumulated 0.14% or 372,052 shares. Omers Administration Corp last reported 0.03% of its portfolio in the stock. Millennium Mngmt Ltd Co accumulated 902,773 shares or 0.02% of the stock. Carl Domino owns 16,800 shares or 0.15% of their US portfolio. Pub Employees Retirement Association Of Colorado last reported 0.01% of its portfolio in the stock. Ibm Retirement Fund last reported 0.01% of its portfolio in the stock. Highbridge Cap Mgmt Limited Liability Com accumulated 166,049 shares or 0.03% of the stock. Moreover, Citadel Ltd Co has 0% invested in Opko Health Inc. (NASDAQ:OPK) for 324,644 shares. Principal Fincl Grp Incorporated Incorporated accumulated 64,988 shares or 0% of the stock. Teton Advsrs holds 0.2% or 238,000 shares in its portfolio. Us National Bank & Trust De reported 5,801 shares or 0% of all its holdings. Cubist Systematic Strategies Llc has 0.01% invested in the company for 20,521 shares. Menora Mivtachim Limited holds 3.04M shares or 1.6% of its portfolio. Hyman Charles D accumulated 18,119 shares or 0.03% of the stock.

Insider Transactions: Since May 26, 2016, the stock had 62 insider purchases, and 0 insider sales for $5.84 million net activity. 11,800 shares were bought by FROST PHILLIP MD ET AL, worth $115,214 on Monday, August 22.

Another recent and important Opko Health Inc. (NASDAQ:OPK) news was published by Seekingalpha.com which published an article titled: “OPKO Health: Significant Growth Potential From FDA Approval” on November 10, 2016.

OPK Company Profile

OPKO Health, Inc. (OPKO), incorporated on November 18, 1991, is a healthcare company. The Firm operates through two divisions: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical activities in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company’s diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The Company’s pharmaceutical business features Rayaldee, a treatment for secondary hyperparathyroidism (SHPT) in patients with stage III or IV chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy-induced nausea and vomiting. The Company’s pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico. The Firm has a development and commercial supply pharmaceutical company, as well as a global supply chain operation and holding firm in Ireland. It also owns a specialty active pharmaceutical ingredients (APIs) maker in Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment